Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers

Author:

Shevach Jeffrey W.1,Candelieri-Surette Danielle2,Lynch Julie A.23,Hubbard Rebecca A.4,Alba Patrick R.23,Glanz Karen5,Parikh Ravi B.67,Maxwell Kara N.678

Affiliation:

1. Division of Medical Oncology, Department of Medicine, Duke University, Durham, NC

2. VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT

3. Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT

4. Department of Biostatistics, Epidemiology & Informatics, University of Pennsylvania, Philadelphia, PA

5. Perelman School of Medicine and School of Nursing, University of Pennsylvania, Philadelphia, PA

6. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

7. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

8. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Abstract

Background: Germline genetic testing is a vital component of guideline-recommended cancer care for males with pancreatic, breast, or metastatic prostate cancers. We sought to determine whether there were racial disparities in germline genetic testing completion in this population. Patients and Methods: This retrospective cohort study included non-Hispanic White and Black males with incident pancreatic, breast, or metastatic prostate cancers between January 1, 2019, and September 30, 2021. Two nationwide cohorts were examined: (1) commercially insured individuals in an administrative claims database, and (2) Veterans receiving care in the Veterans Health Administration. One-year germline genetic testing rates were estimated by using Kaplan-Meier methods. Cox proportional hazards regression was used to test the association between race and genetic testing completion. Causal mediation analyses were performed to investigate whether socioeconomic variables contributed to associations between race and germline testing. Results: Our cohort consisted of 7,894 males (5,142 commercially insured; 2,752 Veterans). One-year testing rates were 18.0% (95% CI, 16.8%–19.2%) in commercially insured individuals and 14.2% (95% CI, 11.5%–15.0%) in Veterans. Black race was associated with a lower hazard of testing among commercially insured individuals (adjusted hazard ratio [aHR], 0.73; 95% CI, 0.58–0.91; P=.005) but not among Veterans (aHR, 0.99; 95% CI, 0.75–1.32; P=.960). In commercially insured individuals, income (aHR, 0.90; 95% CI, 0.86–0.96) and net worth (aHR, 0.92; 95% CI, 0.86–0.98) mediated racial disparities, whereas education (aHR, 0.98; 95% CI, 0.94–1.01) did not. Conclusions: Overall rates of guideline-recommended genetic testing are low in males with pancreatic, breast, or metastatic prostate cancers. Racial disparities in genetic testing among males exist in a commercially insured population, mediated by net worth and household income; these disparities are not seen in the equal-access Veterans Health Administration. Alleviating financial and access barriers may mitigate racial disparities in genetic testing.

Publisher

Harborside Press, LLC

Reference39 articles.

1. Survival with olaparib in metastatic castration-resistant prostate cancer;Hussain M,2020

2. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation;O’Reilly EM,2020

3. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer;Mohler JL,2019

4. NCCN Guidelines updates: pancreatic cancer;Tempero MA,2019

5. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2;Daly MB,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3